{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T02:54:50Z","timestamp":1792896890179,"version":"4.5.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T00:00:00Z","timestamp":1649980800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009242","name":"Direction de l\u2019hospitalisation et de l\u2019offre de Soins","doi-asserted-by":"publisher","award":["TRANSLA12-143"],"award-info":[{"award-number":["TRANSLA12-143"]}],"id":[{"id":"10.13039\/501100009242","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Benzamide-based radioligands targeting melanin were first developed for imaging melanoma and then for therapeutic purpose with targeted radionuclide therapy (TRT).<\/jats:p>\n                <jats:p>[<jats:sup>131<\/jats:sup>I]ICF01012 presents a highly favorable pharmacokinetics profile in vivo for therapy. Tumour growth reduction and increase survival have been established in preclinical models of melanoma. According the these preclinical results, we initiate a first-in-human study aimed to determine the recommended dose of [<jats:sup>131<\/jats:sup>I]ICF01012 to administer for the treatment of patients with pigmented metastatic melanoma.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The MELRIV-1 trial is an open-label, multicentric, dose-escalation phase I trial. The study is divided in 2 steps, a selection part with an IV injection of low activity of [<jats:sup>131<\/jats:sup>I]ICF01012 (185\u2009MBq at D0) to select patients who might benefit from [<jats:sup>131<\/jats:sup>I]ICF01012 TRT in therapeutic part, i.e. patient presenting at least one tumour lesion with [<jats:sup>131<\/jats:sup>I]ICF01012 uptake and an acceptable personalized dosimetry to critical organs (liver, kidney, lung and retina). According to dose escalation scheme driven by a Continual Reassessment Method (CRM) design, a single therapeutic injection of 800\u2009MBq\/m<jats:sup>2<\/jats:sup>, or 1600\u2009MBq\/m<jats:sup>2<\/jats:sup>, or 2700\u2009MBq\/m<jats:sup>2<\/jats:sup> or 4000\u2009MBq\/m<jats:sup>2<\/jats:sup> of [<jats:sup>131<\/jats:sup>I]ICF01012 will be administered at D11 (\u00b1 4\u2009days). The primary endpoint is the recommended therapeutic dose of [<jats:sup>131<\/jats:sup>I]ICF01012, with DLT defined as any grade 3-4 NCI-CT toxicity during the 6\u2009weeks following therapeutic dose. Safety, pharmacokinetic, biodistribution (using planar whole body and SPECT-CT acquisitions), sensitivity \/ specificity of [<jats:sup>131<\/jats:sup>I]ICF01012, and therapeutic efficacy will be assessed as secondary objectives. Patients who received therapeutic injection will be followed until 3\u2009months after TRT. Since 6 to 18 patients are needed for the therapeutic part, up to 36 patients will be enrolled in the selection part.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study is a first-in-human trial evaluating the [<jats:sup>131<\/jats:sup>I]ICF01012 TRT in metastatic malignant melanomas with a diagnostic dose of the [<jats:sup>131<\/jats:sup>I]ICF01012 to select the patients who may benefit from a therapeutic dose of [<jats:sup>131<\/jats:sup>I]ICF01012, with at least one tumor lesion with [<jats:sup>131<\/jats:sup>I]ICF01012 uptake and an acceptable AD to healthy organ.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p><jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">Clinicaltrials.gov<\/jats:ext-link>: <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03784625\">NCT03784625<\/jats:ext-link>. Registered on December 24, 2018.<\/jats:p>\n                <jats:p>Identifier in French National Agency for the Safety of Medicines and Health Products (ANSM): N\u00b0EudraCT 2016-002444-17.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-022-09495-3","type":"journal-article","created":{"date-parts":[[2022,4,15]],"date-time":"2022-04-15T12:02:54Z","timestamp":1650024174000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phase I study of [131I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6833-1971","authenticated-orcid":false,"given":"Emilie","family":"Thivat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques","family":"Rouanet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Auzeloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Sas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Jouberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Levesque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommy","family":"Billoux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Mansard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioana","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Chanchou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Fois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"Maigne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Chezal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabeth","family":"Miot-Noirault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"D\u2019Incan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Durando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florent","family":"Cachin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,4,15]]},"reference":[{"issue":"1","key":"9495_CR1","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1056\/NEJMra052166","volume":"355","author":"AJ Miller","year":"2006","unstructured":"Miller AJ, Mihm MC Jr. Melanoma. N Engl J Med. 2006;355(1):51\u201365.","journal-title":"N Engl J Med"},{"issue":"10","key":"9495_CR2","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/j.annder.2016.07.001","volume":"143","author":"B Guillot","year":"2016","unstructured":"Guillot B, Dalac S, Denis MG, Dupuy A, Emile JF, De La Fouchardiere A, et al. Update to the recommendations for management of melanoma stages I to III. Ann Dermatol Venereol. 2016;143(10):629\u201352.","journal-title":"Ann Dermatol Venereol"},{"issue":"3","key":"9495_CR3","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.annder.2019.01.011","volume":"146","author":"B Guillot","year":"2019","unstructured":"Guillot B, Dupuy A, Pracht M, Jeudy G, Hindie E, Desmedt E, et al. New guidelines for stage III melanoma (the French cutaneous oncology group). Ann Dermatol Venereol. 2019;146(3):204\u201314.","journal-title":"Ann Dermatol Venereol"},{"issue":"8","key":"9495_CR4","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1003466","volume":"363","author":"FS Hodi","year":"2010","unstructured":"Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711\u201323.","journal-title":"N Engl J Med"},{"issue":"3","key":"9495_CR5","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","volume":"15","author":"GA McArthur","year":"2014","unstructured":"McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323\u201332.","journal-title":"Lancet Oncol"},{"issue":"9992","key":"9495_CR6","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","volume":"386","author":"GV Long","year":"2015","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet. 2015;386(9992):444\u201351.","journal-title":"Lancet"},{"issue":"13","key":"9495_CR7","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):1270\u20131.","journal-title":"N Engl J Med"},{"issue":"9","key":"9495_CR8","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1080\/14656566.2019.1601700","volume":"20","author":"R Mason","year":"2019","unstructured":"Mason R, Au L, Ingles Garces A, Larkin J. Current and emerging systemic therapies for cutaneous metastatic melanoma. Expert Opin Pharmacother. 2019;20(9):1135\u201352.","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"9495_CR9","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1053\/j.semnuclmed.2015.12.005","volume":"46","author":"A Norain","year":"2016","unstructured":"Norain A, Dadachova E. Targeted radionuclide therapy of melanoma. Semin Nucl Med. 2016;46(3):250\u20139.","journal-title":"Semin Nucl Med"},{"key":"9495_CR10","doi-asserted-by":"publisher","first-page":"107829","DOI":"10.1016\/j.pharmthera.2021.107829","volume":"224","author":"J Rouanet","year":"2021","unstructured":"Rouanet J, Quintana M, Auzeloux P, Cachin F, Degoul F. Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: preclinical\/clinical development and combination with other treatments. Pharmacol Ther. 2021;224:107829.","journal-title":"Pharmacol Ther"},{"issue":"1","key":"9495_CR11","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2967\/jnumed.112.112789","volume":"55","author":"W Mier","year":"2014","unstructured":"Mier W, Kratochwil C, Hassel JC, Giesel FL, Beijer B, Babich JW, et al. Radiopharmaceutical therapy of patients with metastasized melanoma with the melanin-binding benzamide 131I-BA52. J Nucl Med. 2014;55(1):9\u201314.","journal-title":"J Nucl Med"},{"issue":"8","key":"9495_CR12","first-page":"1573","volume":"32","author":"JM Michelot","year":"1991","unstructured":"Michelot JM, Moreau MF, Labarre PG, Madelmont JC, Veyre AJ, Papon JM, et al. Synthesis and evaluation of new iodine-125 radiopharmaceuticals as potential tracers for malignant melanoma. J Nucl Med. 1991;32(8):1573\u201380.","journal-title":"J Nucl Med"},{"issue":"6","key":"9495_CR13","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/0969-8051(95)00020-X","volume":"22","author":"MF Moreau","year":"1995","unstructured":"Moreau MF, Michelot J, Papon J, Bayle M, Labarre P, Madelmont JC, et al. Synthesis, radiolabeling, and preliminary evaluation in mice of some (N-diethylaminoethyl)-4-iodobenzamide derivatives as melanoma imaging agents. Nucl Med Biol. 1995;22(6):737\u201347.","journal-title":"Nucl Med Biol"},{"issue":"11","key":"9495_CR14","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1007\/s00259-002-0971-6","volume":"29","author":"N Moins","year":"2002","unstructured":"Moins N, D'Incan M, Bonafous J, Bacin F, Labarre P, Moreau MF, et al. 123I-N-(2-diethylaminoethyl)-2-iodobenzamide: a potential imaging agent for cutaneous melanoma staging. Eur J Nucl Med Mol Imaging. 2002;29(11):1478\u201384.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"8","key":"9495_CR15","first-page":"1260","volume":"34","author":"JM Michelot","year":"1993","unstructured":"Michelot JM, Moreau MF, Veyre AJ, Bonafous JF, Bacin FJ, Madelmont JC, et al. Phase II scintigraphic clinical trial of malignant melanoma and metastases with iodine-123-N-(2-diethylaminoethyl 4-iodobenzamide). J Nucl Med. 1993;34(8):1260\u20136.","journal-title":"J Nucl Med"},{"issue":"1","key":"9495_CR16","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/S0181-5512(04)96089-5","volume":"27","author":"I Sillaire-Houtmann","year":"2004","unstructured":"Sillaire-Houtmann I, Bonafous J, Veyre A, Mestas D, D'Incan M, Moins N, et al. Phase 2 clinical study of 123I-N-(2-diethylaminoethyl)-2-iodobenzamide in the diagnostic of primary and metastatic ocular melanoma. J Fr Ophtalmol. 2004;27(1):34\u20139.","journal-title":"J Fr Ophtalmol"},{"issue":"1","key":"9495_CR17","doi-asserted-by":"publisher","first-page":"15","DOI":"10.2967\/jnumed.113.123554","volume":"55","author":"F Cachin","year":"2014","unstructured":"Cachin F, Miot-Noirault E, Gillet B, Isnardi V, Labeille B, Payoux P, et al. (123)I-BZA2 as a melanin-targeted radiotracer for the identification of melanoma metastases: results and perspectives of a multicenter phase III clinical trial. J Nucl Med. 2014;55(1):15\u201322.","journal-title":"J Nucl Med"},{"issue":"11","key":"9495_CR18","doi-asserted-by":"publisher","first-page":"3133","DOI":"10.1021\/jm701424g","volume":"51","author":"JM Chezal","year":"2008","unstructured":"Chezal JM, Papon J, Labarre P, Lartigue C, Galmier MJ, Decombat C, et al. Evaluation of radiolabeled (hetero) aromatic analogues of N-(2-diethylaminoethyl)-4-iodobenzamide for imaging and targeted radionuclide therapy of melanoma. J Med Chem. 2008;51(11):3133\u201344.","journal-title":"J Med Chem"},{"issue":"3","key":"9495_CR19","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/ijc.24413","volume":"125","author":"M Bonnet-Duquennoy","year":"2009","unstructured":"Bonnet-Duquennoy M, Papon J, Mishellany F, Labarre P, Guerquin-Kern JL, Wu TD, et al. Targeted radionuclide therapy of melanoma: anti-tumoural efficacy studies of a new 131I labelled potential agent. Int J Cancer. 2009;125(3):708\u201316.","journal-title":"Int J Cancer"},{"issue":"5","key":"9495_CR20","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1111\/j.1755-148X.2010.00716.x","volume":"23","author":"M Bonnet","year":"2010","unstructured":"Bonnet M, Mishellany F, Papon J, Cayre A, Penault-Llorca F, Madelmont JC, et al. Anti-melanoma efficacy of internal radionuclide therapy in relation to melanin target distribution. Pigment Cell Melanoma Res. 2010;23(5):e1\u201311.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"9495_CR21","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1684\/ejd.2014.2481","volume":"25","author":"C Viallard","year":"2015","unstructured":"Viallard C, Perrot Y, Boudhraa Z, Jouberton E, Miot-Noirault E, Bonnet M, et al. [(1)(2)(3)I]ICF01012 melanoma imaging and [(1)(3)(1)I]ICF01012 dosimetry allow adapted internal targeted radiotherapy in preclinical melanoma models. Eur J Dermatol. 2015;25(1):29\u201335.","journal-title":"Eur J Dermatol"},{"issue":"5","key":"9495_CR22","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1002\/ijc.28103","volume":"133","author":"F Degoul","year":"2013","unstructured":"Degoul F, Borel M, Jacquemot N, Besse S, Communal Y, Mishellany F, et al. In vivo efficacy of melanoma internal radionuclide therapy with a 131I-labelled melanin-targeting heteroarylcarboxamide molecule. Int J Cancer. 2013;133(5):1042\u201353.","journal-title":"Int J Cancer"},{"issue":"11","key":"9495_CR23","doi-asserted-by":"publisher","first-page":"5251","DOI":"10.1002\/mp.13165","volume":"45","author":"E Jouberton","year":"2018","unstructured":"Jouberton E, Perrot Y, Dirat B, Billoux T, Auzeloux P, Cachin F, et al. Radiation dosimetry of [(131) I]ICF01012 in rabbits: application to targeted radionuclide therapy for human melanoma treatment. Med Phys. 2018;45(11):5251\u201362.","journal-title":"Med Phys"},{"issue":"11","key":"9495_CR24","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.1016\/j.tranon.2019.07.015","volume":"12","author":"H Akil","year":"2019","unstructured":"Akil H, Rouanet J, Viallard C, Besse S, Auzeloux P, Chezal JM, et al. Targeted radionuclide therapy decreases melanoma lung invasion by modifying epithelial-mesenchymal transition-like mechanisms. Transl Oncol. 2019;12(11):1442\u201352.","journal-title":"Transl Oncol"},{"issue":"10","key":"9495_CR25","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1007\/s00262-020-02606-8","volume":"69","author":"J Rouanet","year":"2020","unstructured":"Rouanet J, Benboubker V, Akil H, Hennino A, Auzeloux P, Besse S, et al. Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy. Cancer Immunol Immunother. 2020;69(10):2075\u201388.","journal-title":"Cancer Immunol Immunother"},{"key":"9495_CR26","doi-asserted-by":"crossref","unstructured":"Akil H, Quintana M, Raymond JH, Billoux T, Benboubker V, Besse S, Auzeloux P, Delmas V, Petit V, Larue L et al: Efficacy of targeted radionuclide therapy using [(131)I]ICF01012 in 3D pigmented BRAF And NRAS-mutant melanoma models and in vivo NRAS-mutant melanoma. Cancers (Basel) 2021, 13(6).","DOI":"10.3390\/cancers13061421"},{"issue":"1","key":"9495_CR27","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2307\/2531628","volume":"46","author":"J O'Quigley","year":"1990","unstructured":"O'Quigley J, Pepe M, Fisher L. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. Biometrics. 1990;46(1):33\u201348.","journal-title":"Biometrics"},{"issue":"12","key":"9495_CR28","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.2967\/jnumed.113.122390","volume":"54","author":"YK Dewaraja","year":"2013","unstructured":"Dewaraja YK, Ljungberg M, Green AJ, Zanzonico PB, Frey EC, Committee SM, Bolch WE, Brill AB, Dunphy M, Fisher DR, et al. MIRD pamphlet No. 24: Guidelines for quantitative 131I SPECT in dosimetry applications. J Nucl Med. 2013;54(12):2182\u20138.","journal-title":"J Nucl Med"},{"issue":"2","key":"9495_CR29","first-page":"37S","volume":"40","author":"JA Siegel","year":"1999","unstructured":"Siegel JA, Thomas SR, Stubbs JB, Stabin MG, Hays MT, Koral KF, et al. MIRD pamphlet no. 16: techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med. 1999;40(2):37S\u201361S.","journal-title":"J Nucl Med"},{"issue":"1","key":"9495_CR30","doi-asserted-by":"publisher","first-page":"9280","DOI":"10.1038\/s41598-019-45643-9","volume":"9","author":"M Sarna","year":"2019","unstructured":"Sarna M, Krzykawska-Serda M, Jakubowska M, Zadlo A, Urbanska K. Melanin presence inhibits melanoma cell spread in mice in a unique mechanical fashion. Sci Rep. 2019;9(1):9280.","journal-title":"Sci Rep"},{"issue":"3","key":"9495_CR31","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1111\/pcmr.12231","volume":"27","author":"S Dubey","year":"2014","unstructured":"Dubey S, Roulin A. Evolutionary and biomedical consequences of internal melanins. Pigment Cell Melanoma Res. 2014;27(3):327\u201338.","journal-title":"Pigment Cell Melanoma Res"},{"issue":"1","key":"9495_CR32","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/S0936-6555(05)80035-4","volume":"8","author":"NG Burnet","year":"1996","unstructured":"Burnet NG, Wurm R, Nyman J, Peacock JH. Normal tissue radiosensitivity--how important is it? Clin Oncol (R Coll Radiol). 1996;8(1):25\u201334.","journal-title":"Clin Oncol (R Coll Radiol)"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09495-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-022-09495-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-022-09495-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,16]],"date-time":"2022-04-16T13:09:17Z","timestamp":1650114557000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-022-09495-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,15]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9495"],"URL":"https:\/\/doi.org\/10.1186\/s12885-022-09495-3","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,15]]},"assertion":[{"value":"3 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol obtained approval from the French Ethics Committee (Comit\u00e9 de Protection des Personnes Sud Est V, reference: 18-CJPE-01) in November 2018 and from the French National Agency for the Safety of Medicines and Health Products (ANSM) (N\u00b0 EudraCT: 2016-002444-17) in august 2018.The study is conducted in accordance with the Helsinki Declaration, the Good Clinical Practice (GCP) guidelines of the International Conference on Harmonisation (ICH\u2013E6, 17\/07\/96) and local regulatory requirements. Written informed consent will be obtained for each patient before any study-related assessment starts.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"417"}}